|IJCEP Copyright © 2007-All rights reserved.
Int J Clin Exp Pathol 2013;6(10):2102-2111
Expression of Id-1 and VEGF in non-small cell lung cancer
Mee-Seon Kim, Tae-In Park, Yu-Mi Lee, Young-Min Jo, Sunzoo Kim
Department of Pathology, The Regional Cardiocerevbrovascular center, Kyungpook National University Hospital, 130 Dongdeok-ro, Jung-gu,
Deagu, South Korea
Received August 11, 2013; Accepted August 26, 2013; Epub September 15, 2013; Published October 1, 2013
Abstract: Angiogenesis is essential for invasive tumor growth and metastasis. Bevacizumab has been widely used for the treatment of
non-small cell lung cancer (NSCLC). Various studies clearly demonstrate the relevance of Id-1 and VEGF in angiogenesis. The aim of this
study was to establish the role of Id-1 expression in tumor progression and angiogenesis in relation to VEGF in NSCLC. Seventy five patients
underwent surgery for lung cancers. The expressions of Id-1 and VEGF in NSCLC samples were determined by immunohistochemistry.
Expression of Id-1 and VEGF showed a close correlation in NSCLC (p < 0.001). In addition, Id-1 strong expression group showed high
incidence of metastasis in multivariate analysis (p = 0.028). Id-1 strong expression group had short metastasis-free survival (p = 0.008) and
short recurrence-free survival (p = 0.027). Strong Id-1 expression in NSCLC had a poor prognosis in association with VEGF expression. Id-1
may function in tumor growth and progression via angiogenesis. Therefore, Id-1 is considered to be a candidate for new therapeutic target and
a prognostic factor in NSCLC. (IJCEP1308022).
Keywords: Id proteins, vascular endothelial growth factor (VEGF), non-small cell lung cancer, prognosis, metastasis
Address correspondence to: Dr. Sunzoo Kim, Department of Pathology, Kyungpook National University Hospital, 130 Dongdeok-ro, Jung-gu,
Deagu, South Korea. Tel: 82-53-420-5247; Fax: 82-53-426-1525, E-mail: email@example.com; firstname.lastname@example.org